 |
|
|
| |
LEDIPASVIR/SOFOSBUVIR and TENOFOVIR in HIV-HCV co-infected PATIENTS:
IMPACT on TENOFOVIR Ctrough and RENAL SAFETY
|
| |
| |
Reported by Jules Levin
17th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, June 8-10, 2016, Washington DC
C SOLAS1, S BREGIGEON2, V OBRY-ROGUET2, O FAUCHER-ZAEGEL2, S QUARANTA3, C TAMALET4, B LACARELLE1, I POIZOT-MARTIN5
1Aix Marseille Univ, APHM La Timone, Pharmacokinetics and Toxicology-Inserm U911-CRO2 SMARTc, Marseille, France; 2APHM Sainte-Marguerite, Clinical Immuno-Hematology, Marseille, France; 3AP-HM La Timone, Pharmacokinetics and Toxicology, Marseille. France; 4APHM La Timone, Pôle des Maladies Infectieuses et Tropicales Clinique et Biologique, Fédération de Bactériologie-Hygiène-Virologie, Marseille, France; 5Aix Marseille Univ, AP-HM Sainte-Marguerite, Clinical Immuno-Hematology, Inserm U912-SESSTIM, Marseille, France
References:
(1): Mathias A. Drug Interactions Between the anti-HCV Regimen Ledipasvir/Sofosbuvir and Antiretrovirals 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2015 Washington, USA.
(2): Kimberly L. Drug Interactions Between Anti-HCV Antivirals Ledipasvir/Sofosbuvir and Integrase Strand Transfer Inhibitor-Based Regimens 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2015 Washington, USA. Abstr. 71
|
| |
|
|
|
|
|
